Marvin Gee promoted in 3T leadership appointments

San Francisco-based 3T Biosciences, an immunotherapy company in the field of solid tumors and other immune-mediated diseases, has announced the promotion of Marvin Gee (pictured, above) to chief research officer and the appointment of Barbara Sennino as senior vice president and head of early development.

According to the company, these leadership appointments further strengthen 3T’s scientific and translational expertise as the company advances its pipeline of T-cell receptor (TCR)-based therapeutics toward the clinic.

A co-founder of 3T, Dr Gee previously served as vice president and head of research at the company. He has played a key role developing 3T’s proprietary 3T-TRACE and 3T-PRIME discovery platforms and advancing the company’s pipeline of TCR-based therapeutics.